All Pathways
Infectious DiseaseManagement

Tuberculosis Treatment (ATS/CDC/ERS/IDSA 2025)

Tuberculosis Treatment (ATS/CDC/ERS/IDSA 2025): Active Tuberculosis → Initial Workup → Respiratory Isolation → Drug Susceptibility → Drug-Susceptible TB.

Interactive Decision Tree

Mini Map

Algorithm Steps

  1. Start

    Active Tuberculosis

    Pulmonary or extrapulmonary TB confirmed or highly suspected

    1. Action

      Initial Workup

      Before starting treatment

      • Sputum x3 for AFB smear and culture
      • GeneXpert MTB/RIF for rapid detection
      • CXR
      • HIV test (mandatory)
      • Baseline LFTs, CBC, BMP, visual acuity
      1. Action

        Respiratory Isolation

        Airborne precautions

        • Negative pressure room
        • N95 respirators for staff
        • Until 3 negative smears on treatment
        1. Decision

          Drug Susceptibility

          Based on GeneXpert and/or culture

          1. Action

            Drug-Susceptible TB

            Standard 4-drug regimen

            • Intensive phase (2 months): RIPE
            • R: Rifampin 10mg/kg (max 600mg) daily
            • I: Isoniazid 5mg/kg (max 300mg) daily + B6
            • P: Pyrazinamide 25mg/kg daily
            • E: Ethambutol 15-20mg/kg daily
            1. Action

              Continuation Phase

              After 2 months intensive

              • 4 months Rifampin + Isoniazid (total 6 months)
              • NEW: 4-month regimen option:
              • HPZM (INH, RIF, PZA, Moxifloxacin) if age ≥12, drug-susceptible
              • Continue pyridoxine (B6) throughout
              1. Action

                Monitoring

                Clinical and laboratory

                • Monthly sputum until culture negative
                • LFTs at baseline, then if symptomatic
                • Visual acuity monthly while on ethambutol
                • DOT strongly recommended
                1. Warning

                  Hepatotoxicity

                  ALT >5x ULN or symptoms

                  • Stop all hepatotoxic drugs
                  • Rechallenge sequentially after normalization
                  • Consider alternative regimen
                2. Action

                  HIV Co-infection

                  Special considerations

                  • Start ART within 2-8 weeks of TB treatment
                  • Watch for IRIS
                  • Drug interactions: Rifabutin may substitute for rifampin
                  • Longer duration may be needed
                  1. Outcome

                    Treatment Complete

                    6+ months, cultures negative

                3. Warning

                  Treatment Failure/Relapse

                  Persistent positive cultures, recurrence

                  • Re-test for drug resistance
                  • Ensure DOT compliance
                  • Consider surgical resection if localized
          2. Action

            MDR-TB (RIF-resistant)

            Specialist consultation required

            • 6-month BPaLM regimen now recommended:
            • Bedaquiline + Pretomanid + Linezolid + Moxifloxacin
            • OR longer regimen based on DST
            • Expert consultation essential

Guideline Source

ATS/CDC/ERS/IDSA Treatment Guidelines 2025

Clinical Safety Information

Clinical Decision Support — Not a Substitute for Clinical Judgment

Individual patient factors may require deviation from these recommendations.

Known Limitations

  • ⚠️ UNVALIDATED DRAFT: This algorithm was AI-generated from guideline summaries and has NOT been reviewed by clinical experts. All doses, thresholds, and pathways MUST be verified against primary sources by qualified clinicians before clinical use. Do not use for patient care without expert validation.
  • Drug resistance patterns critical
  • HIV coinfection requires special consideration
  • Hepatotoxicity monitoring essential
  • DOT recommended

Applicable Regions

USEU
Version 1Next review: 2027-01-11

Frequently Asked Questions

What is the Tuberculosis Treatment (ATS/CDC/ERS/IDSA 2025)?

The Tuberculosis Treatment (ATS/CDC/ERS/IDSA 2025) is a management clinical algorithm for Infectious Disease. It provides a structured decision tree to guide clinical decision-making, based on ATS/CDC/ERS/IDSA Treatment Guidelines 2025.

What guideline is the Tuberculosis Treatment (ATS/CDC/ERS/IDSA 2025) based on?

This algorithm is based on ATS/CDC/ERS/IDSA Treatment Guidelines 2025 (DOI: 10.1164/rccm.202410-2096ST).

What are the limitations of the Tuberculosis Treatment (ATS/CDC/ERS/IDSA 2025)?

Known limitations include: ⚠️ UNVALIDATED DRAFT: This algorithm was AI-generated from guideline summaries and has NOT been reviewed by clinical experts. All doses, thresholds, and pathways MUST be verified against primary sources by qualified clinicians before clinical use. Do not use for patient care without expert validation.; Drug resistance patterns critical; HIV coinfection requires special consideration; Hepatotoxicity monitoring essential; DOT recommended. Individual patient factors may require deviation from these recommendations.

Get AI-Powered Analysis Alongside This Algorithm

In AttendMe.ai, the Tuberculosis Treatment (ATS/CDC/ERS/IDSA 2025) appears automatically when your clinical question matches — alongside evidence from 3M+ peer-reviewed articles.

Try AttendMe Free